October 02, 2012

Lyxumia® (lixisenatide)* in Combination with Basal Insulin plus Oral Anti-Diabetics Significantly Improved Glycemic Control

– Data show investigational GLP-1 receptor agonist delayed gastric emptying and significantly reduced post-prandial glucose –
– Results from the GetGoal Duo 1 and GetGoal-L Phase III studies also presented at the annual EASD meeting –

 

Lyxumia® (lixisenatide)* in Combination with Basal Insulin plus Oral Anti-Diabetics Significantly Improved Glycemic Control
– Data show investigational GLP-1 receptor agonist delayed gastric emptying and significantly reduced post-prandial glucose –
– Results from the GetGoal Duo 1 and GetGoal-L Phase III studies also presented at the annual EASD meeting –

Paris, France – October 2, 2012 – Sanofi (EURONEXT: SAN and NYSE: SNY) today announced results from a study showing that the mechanism of action of once-daily Lyxumia® (lixisenatide) significantly delayed gastric emptying, a process accompanied by significant post-prandial glucose (PPG) lowering. These data were presented at the 48th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Berlin, alongside Phase III trial results that support the clinical rationale for lixisenatide as a potential once-daily GLP-1 receptor agonist (RA) in combination with basal insulin.